Cargando…

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

OBJECTIVE: Obtain a more precise estimate of the efficacy of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) in relapsing multiple sclerosis (MS) and examine the consistency of DMF's effects across patient subgroups stratified by baseline demographic and disease char...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viglietta, Vissia, Miller, David, Bar-Or, Amit, Phillips, J Theodore, Arnold, Douglas L, Selmaj, Krzysztof, Kita, Mariko, Hutchinson, Michael, Yang, Minhua, Zhang, Ray, Dawson, Katherine T, Sheikh, Sarah I, Fox, Robert J, Gold, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338952/ https://www.ncbi.nlm.nih.gov/pubmed/25750916 http://dx.doi.org/10.1002/acn3.148

Ejemplares similares

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
por: Miller, David H., et al.
Publicado: (2015)

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience
por: Gold, Ralf, et al.
Publicado: (2015)

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE
por: Gold, Ralf, et al.
Publicado: (2020)

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM
por: Fox, Robert J., et al.
Publicado: (2017)

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
por: Gold, Ralf, et al.
Publicado: (2021)

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies
por: Gold, Ralf, et al.
Publicado: (2016)

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
por: Havrdova, E., et al.
Publicado: (2017)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
por: Kappos, L, et al.
Publicado: (2015)

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations
por: Fox, Robert J., et al.
Publicado: (2016)

Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017)

A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries
por: Saida, Takahiko, et al.
Publicado: (2019)

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019)

Dimethyl Fumarate-Induced Takotsubo Cardiomyopathy in a Patient With Relapsing-Remitting Multiple Sclerosis
por: Srichawla, Bahadar S
Publicado: (2022)

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2014)

Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
por: Eriksson, Irene, et al.
Publicado: (2017)

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Carlström, Karl E., et al.
Publicado: (2019)

Advances in the management of relapsing–remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)
por: Nielsen, A Scott
Publicado: (2015)

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
por: Alroughani, Raed, et al.
Publicado: (2021)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
por: Ginestal, Ricardo, et al.
Publicado: (2023)

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019)

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)
por: Gold, Ralf, et al.
Publicado: (2018)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
por: Naismith, Robert T., et al.
Publicado: (2020)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Kawalec, Paweł, et al.
Publicado: (2014)

Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
por: Narapureddy, Bhavya, et al.
Publicado: (2019)

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
por: Amezcua, Lilyana, et al.
Publicado: (2023)

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
por: Singer, Barry A, et al.
Publicado: (2023)

Relapsing–Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment
por: Cunill, Vanesa, et al.
Publicado: (2018)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
por: Allan, Michelle, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7ee231hhm4jonr5ko447s4d6jg